Introduction
Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a type of monoclonal antibody that specifically targets the CD134/TNFRSF4/OX40 protein in humans. This protein is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of immune responses. In this article, we will discuss the structure, activity, and applications of this antibody.
Structure of Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639)
Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity for its target protein. It is composed of two heavy chains and two light chains, each with a specific amino acid sequence. These chains are connected by disulfide bonds to form a Y-shaped structure.
The variable regions of the antibody, also known as the antigen-binding regions, are responsible for binding to the CD134/TNFRSF4/OX40 protein. These regions are highly specific and allow the antibody to recognize and bind to its target with high affinity.
Activity of Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639)
The main activity of Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is to block the activity of the CD134/TNFRSF4/OX40 protein. This protein is primarily expressed on the surface of activated T cells and plays a crucial role in regulating T cell activation and proliferation.
By binding to the CD134/TNFRSF4/OX40 protein, the antibody prevents its interaction with its ligand, which is necessary for T cell activation. This results in the inhibition of T cell proliferation and cytokine production, which are important processes in the immune response.
Applications of Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639)
Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) has been extensively studied for its potential therapeutic applications in various diseases, including cancer and autoimmune disorders.
One of the main applications of this antibody is in cancer immunotherapy. By blocking the activity of the CD134/TNFRSF4/OX40 protein, the antibody can inhibit the growth and survival of cancer cells. It has been shown to be effective in pre-clinical studies for the treatment of various types of cancer, including melanoma, breast cancer, and lung cancer.
In addition, this antibody has also shown promising results in the treatment of autoimmune disorders. By inhibiting T cell activation, it can reduce the production of inflammatory cytokines and prevent tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.
Furthermore, Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) has also been used in research studies to investigate the role of the CD134/TNFRSF4/OX40 pathway in various diseases. It has been used to study the mechanism of action of the protein and to identify potential therapeutic targets for the treatment of diseases.
Conclusion
In summary, Anti-Human CD134/TNFRSF4/OX40 Monoclonal Antibody (1A639) is a highly specific and potent antibody that targets the CD134/TNFRSF4/OX40 protein. Its structure allows for high affinity binding to its target, and its main activity is to block the function of the CD134/TNFRSF4/OX40 protein. This antibody has shown promising results in cancer immunotherapy and the treatment of autoimmune disorders, and it continues to be an important tool in research studies investigating the role of the CD134/TNFRSF4/OX40 pathway in
There are no reviews yet.